Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:Japan
|
| gptkbp:ATCCode |
L01XX77
|
| gptkbp:CASNumber |
1801633-27-3
|
| gptkbp:developedBy |
gptkb:Daiichi_Sankyo
|
| gptkbp:hasMolecularFormula |
C23H28N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Valemetostat
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
EZH1/2 dual inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:EZH2
gptkb:EZH1 |
| gptkbp:UNII |
6Q1K1Q0K1E
|
| gptkbp:usedFor |
treatment of relapsed or refractory adult T-cell leukemia/lymphoma
|
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|